EMENDO

Dead / Abandoned — Abandoned — after inter partes decision (as of 24 Mar 2025)

What this means for you

This application is over — abandoned 24 Mar 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number
90798013
Mark type
Stylized text
Filed
28 Jun 2021
Published for opposition
27 Dec 2022
Abandoned
24 Mar 2025
Attorney of record
LAUREN GREGORY LEIPOLD

Goods and services

  • Class 001 — Chemicals: Enzymes for scientific and research purposes; nucleases and nuclease panels for scientific and research purposes; nucleases and nuclease panels derived from biotechnological processes for use in scientific and research purposes; assays and reagents for use in genetic research; nucleases and nuclease panels for use in genetic research
  • Class 005 — Pharmaceuticals: Enzyme preparations for medical purposes; enzymes for medical purposes; nucleases and nuclease panels for medical purposes; reagents for use in medical genetic testing; preparations for detecting genetic predispositions for medical purposes; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the prevention of diseases or decisions caused by genetic predispositions; pharmaceutical preparations for editing of faulty genes; chemical preparations for pharmaceutical or medical purposes, namely, for editing of faulty genes; anti-cancer preparations; pharmaceutical products for the prevention and treatment of cancer; ocular pharmaceuticals; pharmaceutical preparations and substances for the treatment of genetic blood disorders
  • Class 042 — Scientific and technological services: Testing, research, or development of pharmaceutical preparations for gene therapy; testing, research, selection, optimization or development of nucleases for gene targeting, gene editing, or gene therapy; DNA analysis services for scientific research purposes; genetic testing for scientific research purposes; scientific research in the field of genetics, gene editing and genetic engineering; providing medical and scientific research information in the fields of pharmaceuticals and genetics; scientific research consulting in the field of genetics; scientific research consulting in the field of gene editing; scientific research consulting in the field of selection and optimization of nucleases for gene editing and pharmaceutical development; scientific research in the field of selection and optimization of nucleases for gene editing and pharmaceutical development; pharmaceutical research services, excluding production technologies; pharmaceutical research and development, excluding production technologies; pharmaceutical products development; pharmaceutical product evaluation; pharmaceutical drug development services, excluding production technologies; development of pharmaceutical preparations and medicines; technical research in the field of pharmaceutical studies, excluding production technologies; research and development in the pharmaceutical and biotechnology fields, excluding production technologies; testing of pharmaceuticals; laboratory research services relating to pharmaceuticals; conducting early evaluations in the field of new pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical research services in the field of cancer; medical research services in the field of genetic blood disorders; medical research services in the field of genetic ocular disorders; medical and scientific research in the field of cancer treatment and diagnosis; scientific research for medical purposes in the field of gene editing and genetic disorders; scientific research for medical purposes in the field of nuclease and nuclease panel discovery and optimization for the development of gene-targeting pharmaceuticals

Owner

Prosecution history

  • 24 Mar 2025 — ABANDONMENT NOTICE E-MAILED - INTER PARTES DECISION
  • 24 Mar 2025 — ABANDONMENT - AFTER INTER PARTES DECISION
  • 24 Mar 2025 — OPPOSITION TERMINATED NO. 999999
  • 24 Mar 2025 — OPPOSITION DISMISSED NO. 999999
  • 10 Mar 2025 — ASSIGNED TO EXAMINER
  • 26 Jun 2023 — OPPOSITION INSTITUTED NO. 999999
  • 24 Jan 2023 — EXTENSION OF TIME TO OPPOSE RECEIVED
  • 27 Dec 2022 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 27 Dec 2022 — PUBLISHED FOR OPPOSITION
  • 07 Dec 2022 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 22 Nov 2022 — APPROVED FOR PUB - PRINCIPAL REGISTER
  • 03 Nov 2022 — TEAS/EMAIL CORRESPONDENCE ENTERED
  • 03 Nov 2022 — CORRESPONDENCE RECEIVED IN LAW OFFICE
  • 03 Nov 2022 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
  • 03 May 2022 — NOTIFICATION OF NON-FINAL ACTION E-MAILED

View this trademark record on Marksy